Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0EQ3O
|
|||
| Drug Name |
Pyrazolo[1,5-a]pyrimidine derivative 4
|
|||
| Synonyms |
PMID26161824-Compound-134
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Obesity [ICD-11: 5B81; ICD-10: E66; ICD-9: 278] | Patented | [1] | |
| Company |
Mitsubishi Tanabe Pharma Corporation MORITANI, Yasunori SHIRAI, Kimihiro OI, Marik
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C26H17Cl2F3N6O
|
|||
| Canonical SMILES |
CN(C1=CC=CC=N1)NC(=O)C2=C3N=CC(=C(N3N=C2C(F)(F)F)C4=CC=C(C=C4)Cl)C5=CC=CC=C5Cl
|
|||
| InChI |
1S/C26H17Cl2F3N6O/c1-36(20-8-4-5-13-32-20)35-25(38)21-23(26(29,30)31)34-37-22(15-9-11-16(27)12-10-15)18(14-33-24(21)37)17-6-2-3-7-19(17)28/h2-14H,1H3,(H,35,38)
|
|||
| InChIKey |
BOANGAFVCNVTRF-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Cannabinoid receptor 1 (CB1) | Target Info | Antagonist | [1] |
| Target's Patent Info | Cannabinoid receptor 1 (CB1) | Target's Patent Info | [1] | |
| KEGG Pathway | Rap1 signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Retrograde endocannabinoid signaling | ||||
| Panther Pathway | Endogenous cannabinoid signaling | |||
| Pathway Interaction Database | N-cadherin signaling events | |||
| Reactome | Class A/1 (Rhodopsin-like receptors) | |||
| G alpha (i) signalling events | ||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | |||
| Small Ligand GPCRs | ||||
| BDNF signaling pathway | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| GPCRs, Other | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.